Legionella pneumonia is a severe form of pneumonia caused by the bacterium Legionella pneumophila. It often presents with atypical symptoms and can lead to complications such as rhabdomyolysis and acute kidney injury (AKI). Here, we report a case of Legionella pneumonia-induced rhabdomyolysis and AKI in a 32-year-old male. Laboratory investigations revealed elevated creatinine kinase levels and acute kidney injury. Further investigation confirmed Legionella pneumonia. The patient was promptly treated with appropriate antibiotics and supportive care, resulting in clinical improvement and resolution of rhabdomyolysis and AKI. This case underscores the importance of considering Legionella pneumonia as a potential cause of rhabdomyolysis and AKI, especially in patients with atypical pneumonia presentations.

2024-05-01·American Journal of Perinatology

Medical Marijuana Legalization in Oklahoma: Effects on Neonatal Exposure to Opiates

Article

作者: Szyld, Edgardo ; Beasley, William H. ; DeShea, Lise ; Rolfs, Shanna ; Makkar, Abhishek ; McCoy, Mike

Objective The U.S. opioid epidemic has been characterized by increases in opioid misuse, overdose deaths, and neonatal opioid withdrawal syndrome. Research suggests that marijuana legalization has contributed to decreased use of opiates, although many studies had methodological weaknesses and failed to address the pregnant population. Implementation of medical cannabis laws has the potential to reduce maternal opioid use and, therefore, neonatal exposure to the drugs. This study aimed to examine the association between Oklahoma's implementation of state medical marijuana laws and the neonatal exposure to opioids. Study Design Electronic medical records at two sites (Oklahoma City and Lawton) were searched for results of cord, urine, and meconium screens to detect amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, opiates, phencyclidine, and tetrahydrocannabinol (THC). Two study periods were compared: 19 months before Oklahoma's medical marijuana law took effect and 19 months after legalization began. Results A total of 16,804 babies were born alive at the two sites during the study period. The rate of positive THC tests per 1,000 liveborn infants significantly increased from 16.2 per 1,000 during the prelaw period to 22.2 per 1,000 during the postlaw period (p = 0.004). Neonatal opioid exposure incidence showed a nonsignificant decrease from 7.6 positive tests per 1,000 liveborn infants to 6.8 per 1,000 from prelaw to postlaw period (p = 0.542). The number of positive tests for THC and concomitant use of opioids doubled from the prelaw period (n = 4) to postlaw (n = 9), but there were too few cases for statistical significance. Infants at the more rural site had significantly higher rates for amphetamines, benzodiazepines, and THC, with a trend toward higher rates for opiates. Conclusion Marijuana legalization was related to significant increases in positive test rates for THC, but no significant change/association was noted for neonatal exposure to opioids. Key Points

2024-04-13·Cureus

Pneumocystis jirovecii Pneumonia Complicated by Pneumomediastinum: A Case Report

作者: Khan, Muhammad H ; Mada, Pradeep Kumar

Pneumomediastinum refers to the presence of air in the mediastinum (the space in the chest between the lungs). It can arise from various etiologies, including trauma, esophageal perforation, infections, medical procedures, or underlying lung diseases. Pneumocystis jirovecii pneumonia (PJP) is a common opportunistic infection seen in immunocompromised individuals, especially those with HIV/AIDS. Pneumomediastinum is a rare but serious complication of PJP that occurs in immunosuppressed patients, leading to significant morbidity and mortality. We present a rare case of pneumomediastinum caused by P. jirovecii pneumonia in an AIDS patient.

项与 Comanche County Memorial Hospital 相关的新闻（医药）

2023-01-09

·GlobeNewswire-Health Care

TELA Bio Announces U.S. Commercial Launch of NIVIS™ Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds

Company grows product portfolio, expanding product offerings to optimize soft tissue preservation and restorationMALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced the commercial launch of its NIVIS Fibrillar Collagen Pack. NIVIS Fibrillar Collagen Pack is an absorbent matrix of Type I and Type III bovine collagen designed to manage moderately to heavily exudating wounds and to control minor bleeding. Type I and Type III collagen closely resemble the native collagen of a patient and have been shown to stimulate cellular activity and contribute to new tissue development. Specifically, Type III collagen helps control wound contraction and the amount of scar deposition during wound healing. NIVIS is provided in particulate form allowing it to be molded and packed into wounds facilitating contact with host tissue. “Surgical wound management can be a source of concern, especially in patients considered higher risk for complications,” said Dr. Michael Sawyer, General Surgeon at Comanche County Memorial Hospital. “While there are various options to treat these patients, I’m encouraged by both the handling and initial clinical utility I’ve experienced with NIVIS.” In April 2022, TELA Bio entered an exclusive development and distribution partnership for Collagen Matrix, Inc.’s proprietary fibrillar collagen pack in the USA. NIVIS Fibrillar Collagen Pack builds on TELA Bio’s soft-tissue preservation and restoration mission which prioritizes leveraging the patient’s natural healing response. “The commercial launch of NIVIS is a meaningful step forward in our commitment to provide a suite of effective soft tissue repair solutions for our growing customer base in general, and plastics and reconstructive surgery,” said Antony Koblish, President and CEO of TELA Bio. “NIVIS is a high-quality product that complements our OviTex® portfolio perfectly and provides a new vehicle of growth for the company.” About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com. About NIVIS™ Fibrillar Collagen Pack NIVIS Fibrillar Collagen Pack is indicated for the management of moderately to heavily exudating wounds and to control minor bleeding. NIVIS Fibrillar Collagen Pack may be used for the management of exudating wounds such as pressure ulcers, venous stasis ulcers, diabetic ulcers, acute wounds, for example trauma and surgical wounds, and partial-thickness burns. Do not use NIVIS in patients known to be sensitive to materials of Bovine (cow) origin. Use of NIVIS in this patient population may result in an allergic or immunological reaction. Some reactions such as transitory pain, bleeding, blistering, swelling and redness have been reported in isolated cases using a similar product. For additional important safety information, please see the NIVIS Instructions for Use. About Collagen Matrix, Inc. Collagen Matrix, Inc. is a developer and manufacturer of collagen-based medical products used for tissue and bone repair and regeneration. Founded in 1997, Collagen Matrix is headquartered in Oakland, New Jersey and develops proprietary products that are sold to OEM customers on either a contract or private label basis across orthopedic, sports medicine, dental, ear, nose and throat, advanced wound, and neurosurgery end markets. The company also offers partnership opportunities including distribution, contract product development, and contract manufacturing services. For more information, please visit www.collagenmatrix.com. Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management, including with respect to the commercial launch of NIVIS. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor ContactGreg Chodaczek347-620-7010 ir@telabio.com Media ContactAlyson Kuritz908-892-7149alyson@0to5.com

100 项与 Comanche County Memorial Hospital 相关的药物交易

登录后查看更多信息

100 项与 Comanche County Memorial Hospital 相关的转化医学

登录后查看更多信息